Akari Therapeutics (AKTX) Net Equity Issued and Repurchased (2012 - 2025)

Akari Therapeutics (AKTX) posted quarterly Net Equity Issued and Repurchased of $479560.0 for Q4 2025, down 84.67% year-on-year from $3.1 million in Q4 2024, and down 89.99% on a QoQ basis from $4.8 million in Q2 2025.

Akari Therapeutics (AKTX) Net Equity Issued and Repurchased (2012 - 2025) Analysis & Trends

Akari Therapeutics (AKTX) has reported Net Equity Issued and Repurchased for 8 consecutive years, with $479560.0 the latest figure, recorded in Q4 2025.

  • Quarterly Net Equity Issued and Repurchased fell 84.67% year-over-year to $479560.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.4 million (down 46.18% YoY) and the FY2025 annual result came in at $10.7 million, down 9.23% from the prior year.
  • Net Equity Issued and Repurchased retreated to $479560.0 in Q4 2025 per AKTX's latest filing, from $4.8 million in the prior quarter.
  • Over the last five years, Net Equity Issued and Repurchased for AKTX reached as high as $7.1 million in Q2 2024 and fell as low as -$133000.0 in Q3 2024.
  • A 4-year average of $2.8 million and a median of $1.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
  • The largest YoY upside for Net Equity Issued and Repurchased was 73.78% in 2024 against a maximum downside of 107.82% in 2024.
  • Year by year, Net Equity Issued and Repurchased stood at $5.4 million in 2021, then tumbled by 66.67% to $1.8 million in 2023, then soared by 73.78% to $3.1 million in 2024, then plunged by 84.67% to $479560.0 in 2025.
  • According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $479560.0, $4.8 million, and $1.1 million for Q4 2025, Q2 2025, and Q1 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Akari Therapeutics 86.55 Mn 86.55 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 479,560.00
Dec 31, 2025 479,560.00
Jun 30, 2025 4.79 Mn
Jun 30, 2025 4.79 Mn
Mar 31, 2025 1.09 Mn
Mar 31, 2025 1.09 Mn
Dec 31, 2024 3.13 Mn
Dec 31, 2024 3.13 Mn
Sep 30, 2024 -133,000.00
Sep 30, 2024 -133,000.00
Jun 30, 2024 7.12 Mn
Jun 30, 2024 7.12 Mn
Mar 31, 2024 1.70 Mn
Mar 31, 2024 1.70 Mn
Dec 31, 2023 1.80 Mn
Dec 31, 2023 1.80 Mn
Sep 30, 2023 1.70 Mn
Sep 30, 2023 1.70 Mn
Mar 31, 2023 3.50 Mn
Mar 31, 2023 3.50 Mn